Stay updated with breaking news from Al Reba. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/CNW Telbec/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO® (nivolumab) 360 mg every three weeks or 3mg/kg every two...
First new systemic therapy in more than 15 years for cancer related to asbestos exposure Today, Bristol Myers Squibb Canada announced Health Canada's approval of OPDIVO ® 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® 1 mgkg every six weeks for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM. i This is the ...
Learn more about Acute Myeloid Leukemia and ONUREG (CNW Group/Bristol Myers Squibb Canada Co.) AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure, and is the most common form of acute leukemia in adults, accounting for approximately 80 per cent of adult cases. 2,3,4 An estimated 40-60 per cent of patients aged 60 years and older and 60-80 per cent of patients under 60 years old will obtain complete remission through induction chemotherapy (IC); however, 50 per cent will relapse within a year. 5,6 Once a relapse occurs, long-term...